Remove 2030 Remove Competition Remove Healthcare
article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

The Inflation Reduction Act’s health insurance subsidies and drug pricing reforms will improve health care affordability for Americans but won’t do a damn thing for our overall healthcare costs, which will keep rising. 1ne: A new analysis predicts that by 2030, 48.9% A staggering 85% of healthcare costs in the U.S.

article thumbnail

12 Strategies to Increase Patient Engagement in Healthcare

LEVO Health

As healthcare practices strive to navigate the complexities of patient needs and preferences, the importance of fostering robust patient engagement strategies cannot be overstated. The Importance of Patient Engagement Personalization for patients is a key driver of improved healthcare outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Who’s saying what? Blockchain mentions in company filings of pharmaceutical industry increased by 17% in Q1 2023

Pharmaceutical Technology

GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors. For further understanding of GlobalData's Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 buy the report here.

article thumbnail

Vaccines Europe launches first pipeline review

European Pharmaceutical Review

Increase awareness of the benefits of adult vaccination among citizens and healthcare professionals. healthcare budget on?immunisation, Vaccines Europe states that the actions must be addressed to ensure the European Beating Cancer Plan and the Immunization Agenda 2030 are met. percent of their?healthcare

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

Bayer sells testosterone drug rights to Grünenthal for €500m

pharmaphorum

Bayer’s venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as the group continues a revamp of its healthcare business. The two companies said the transaction is expected to close by the end of 2022, subject to approval by the competition authorities.

article thumbnail

Is Medical Sales Still A Lucrative Job?

Contrarian Sales Techniques

According to the Bureau of Labor Statistics, employment of medical and pharmaceutical sales representatives is projected to grow 3 percent from 2020 to 2030, about as fast as the average for all occupations. However, the industry is becoming more competitive and navigating the industry is becoming harder.